These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 27393507)

  • 1. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.
    Ou SI; Agarwal N; Ali SM
    Lung Cancer; 2016 Aug; 98():59-61. PubMed ID: 27393507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.
    Wang Y; Li L; Han R; Jiao L; Zheng J; He Y
    Lung Cancer; 2018 Apr; 118():105-110. PubMed ID: 29571987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.
    Nishiyama A; Takeuchi S; Adachi Y; Otani S; Tanimoto A; Sasaki M; Matsumoto S; Goto K; Yano S
    Cancer Sci; 2020 Oct; 111(10):3813-3823. PubMed ID: 32735723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
    Wang Y; Tian P; Xia L; Li L; Han R; Zhu M; Lizaso A; Qin T; Li M; Yu B; Mao X; Han-Zhang H; He Y
    Lung Cancer; 2020 Aug; 146():165-173. PubMed ID: 32540560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
    Wang CG; Zeng DX; Huang JA; Jiang JH
    Medicine (Baltimore); 2018 Jan; 97(1):e9021. PubMed ID: 29505507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
    Chabon JJ; Simmons AD; Lovejoy AF; Esfahani MS; Newman AM; Haringsma HJ; Kurtz DM; Stehr H; Scherer F; Karlovich CA; Harding TC; Durkin KA; Otterson GA; Purcell WT; Camidge DR; Goldman JW; Sequist LV; Piotrowska Z; Wakelee HA; Neal JW; Alizadeh AA; Diehn M
    Nat Commun; 2016 Jun; 7():11815. PubMed ID: 27283993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
    Nanjo S; Yamada T; Nishihara H; Takeuchi S; Sano T; Nakagawa T; Ishikawa D; Zhao L; Ebi H; Yasumoto K; Matsumoto K; Yano S
    PLoS One; 2013; 8(12):e84700. PubMed ID: 24386407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.
    Wang Q; Yang S; Wang K; Sun SY
    J Hematol Oncol; 2019 Jun; 12(1):63. PubMed ID: 31227004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.
    Knebel FH; Bettoni F; Shimada AK; Cruz M; Alessi JV; Negrão MV; Reis LFL; Katz A; Camargo AA
    Lung Cancer; 2017 Jun; 108():238-241. PubMed ID: 28625643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
    Remon J; Planchard D
    Future Oncol; 2015 Nov; 11(22):3069-81. PubMed ID: 26450446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Lee K; Kim D; Yoon S; Lee DH; Kim SW
    Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
    Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
    Planchard D; Loriot Y; André F; Gobert A; Auger N; Lacroix L; Soria JC
    Ann Oncol; 2015 Oct; 26(10):2073-8. PubMed ID: 26269204
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
    Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.